tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

GPCR Stock Latest News

Leveraging External Amylin Validation: Positioning Structure Therapeutics’ Amylin and Oral GLP‑1 Platform for Combination-Driven Upside
RatingsLeveraging External Amylin Validation: Positioning Structure Therapeutics’ Amylin and Oral GLP‑1 Platform for Combination-Driven Upside
8d ago
GPCR
Structure Therapeutics price target raised to $114 from $90 at H.C. Wainwright
PremiumThe Fly
Structure Therapeutics price target raised to $114 from $90 at H.C. Wainwright
12d ago
GPCR
Structure Therapeutics price target lowered to $113 from $120 at Citizens
PremiumThe Fly
Structure Therapeutics price target lowered to $113 from $120 at Citizens
15d ago
GPCR
Buy Rating on Structure Therapeutics: Strong Phase II Data and Upcoming Late‑Stage Catalysts Support Upside for Oral GLP‑1 Aleniglipron
PremiumRatings
Buy Rating on Structure Therapeutics: Strong Phase II Data and Upcoming Late‑Stage Catalysts Support Upside for Oral GLP‑1 Aleniglipron
16d ago
GPCR
Midday Fly By: Warsh nominated for Fed chair, Apple reports Q1 beat
PremiumThe Fly
Midday Fly By: Warsh nominated for Fed chair, Apple reports Q1 beat
1M ago
V
CL
Structure Therapeutics emerges as top M&A target for big pharma, Axios says
PremiumThe FlyStructure Therapeutics emerges as top M&A target for big pharma, Axios says
1M ago
GPCR
Structure Therapeutics price target raised to $105 from $65 at JPMorgan
Premium
The Fly
Structure Therapeutics price target raised to $105 from $65 at JPMorgan
2M ago
GPCR
Structure Therapeutics price target raised to $140 from $90 at Guggenheim
Premium
The Fly
Structure Therapeutics price target raised to $140 from $90 at Guggenheim
2M ago
GPCR
Structure Therapeutics moved to Buy rating at Goldman Sachs
PremiumThe Fly
Structure Therapeutics moved to Buy rating at Goldman Sachs
2M ago
LLY
GPCR
Novo Nordisk’s renewed M&A appetite sends obesity-drug names higher
PremiumThe Fly
Novo Nordisk’s renewed M&A appetite sends obesity-drug names higher
2M ago
LLY
NVO
Novo Nordisk says back on the hunt for obesity deals, Bloomberg reports
PremiumThe Fly
Novo Nordisk says back on the hunt for obesity deals, Bloomberg reports
2M ago
LLY
NVO
Structure Therapeutics rises 14.1%
PremiumThe Fly
Structure Therapeutics rises 14.1%
2M ago
GPCR
Validating IP, Extending Runway: Why Structure Therapeutics’ Oral GLP‑1 Platform Supports a Buy Rating
PremiumRatingsValidating IP, Extending Runway: Why Structure Therapeutics’ Oral GLP‑1 Platform Supports a Buy Rating
2M ago
GPCR
Structure Therapeutics inks major GLP-1 licensing deal
Premium
Company Announcements
Structure Therapeutics inks major GLP-1 licensing deal
2M ago
8K
GPCR
Structure Therapeutics price target raised to $90 from $60 at H.C. Wainwright
Premium
The Fly
Structure Therapeutics price target raised to $90 from $60 at H.C. Wainwright
3M ago
GPCR
Structure Therapeutics announces initiation of Phase 1 study of ACCG-2671
PremiumThe Fly
Structure Therapeutics announces initiation of Phase 1 study of ACCG-2671
3M ago
GPCR
Structure Therapeutics price target raised to $125 from $120 at Morgan Stanley
PremiumThe Fly
Structure Therapeutics price target raised to $125 from $120 at Morgan Stanley
3M ago
GPCR
Structure Therapeutics price target raised to $120 from $87 at Citizens
PremiumThe Fly
Structure Therapeutics price target raised to $120 from $87 at Citizens
3M ago
GPCR
Structure Therapeutics price target raised to $125 from $79 at Jefferies
PremiumThe Fly
Structure Therapeutics price target raised to $125 from $79 at Jefferies
3M ago
GPCR
Structure Therapeutics Announces $650 Million Public Offering
PremiumCompany AnnouncementsStructure Therapeutics Announces $650 Million Public Offering
3M ago
8K
GPCR
Structure Therapeutics 8.5M share Spot Secondary priced at $65.00
Premium
The Fly
Structure Therapeutics 8.5M share Spot Secondary priced at $65.00
3M ago
GPCR
Structure Therapeutics Stock (GPCR) Spikes 102% as Obesity Trial Beats Eli Lilly, Novo Nordisk
Premium
Market News
Structure Therapeutics Stock (GPCR) Spikes 102% as Obesity Trial Beats Eli Lilly, Novo Nordisk
3M ago
LLY
NVO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >